These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 29623210

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Nivolumab-induced type 1 diabetes mellitus as an immune-related adverse event.
    Yilmaz M.
    J Oncol Pharm Pract; 2020 Jan; 26(1):236-239. PubMed ID: 30955467
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A Case of Severe Diabetic Ketoacidosis Associated with Pembrolizumab Therapy in a Patient with Metastatic Melanoma.
    Wu L, Li B.
    Diabetes Metab Syndr Obes; 2021 Jan; 14():753-757. PubMed ID: 33628041
    [Abstract] [Full Text] [Related]

  • 10. Nivolumab, an Anti-Programmed Cell Death-1 Antibody, Induces Fulminant Type 1 Diabetes.
    Miyoshi Y, Ogawa O, Oyama Y.
    Tohoku J Exp Med; 2016 Jun; 239(2):155-8. PubMed ID: 27297738
    [Abstract] [Full Text] [Related]

  • 11. A case of pembrolizumab-induced severe DKA and hypothyroidism in a patient with metastatic melanoma.
    Hakami OA, Ioana J, Ahmad S, Tun TK, Sreenan S, McDermott JH.
    Endocrinol Diabetes Metab Case Rep; 2019 Mar 05; 2019():. PubMed ID: 30836329
    [Abstract] [Full Text] [Related]

  • 12. Rapid-onset diabetic ketoacidosis secondary to nivolumab therapy.
    Lee S, Morgan A, Shah S, Ebeling PR.
    Endocrinol Diabetes Metab Case Rep; 2018 Mar 05; 2018():. PubMed ID: 29732161
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Ketosis-prone diabetes and SLE co-presenting in an African lady with previous gestational diabetes.
    Hussain S, Keat S, Gelding SV.
    Endocrinol Diabetes Metab Case Rep; 2017 Mar 05; 2017():. PubMed ID: 29026609
    [Abstract] [Full Text] [Related]

  • 16. New-onset type 1 diabetes mellitus as a delayed immune-related event after discontinuation of nivolumab: A case report.
    Seo JH, Lim T, Ham A, Kim YA, Lee M.
    Medicine (Baltimore); 2022 Sep 02; 101(35):e30456. PubMed ID: 36107574
    [Abstract] [Full Text] [Related]

  • 17. Painless Thyroiditis and Fulminant Type 1 Diabetes Mellitus in a Patient Treated with an Immune Checkpoint Inhibitor, Nivolumab.
    Sakurai K, Niitsuma S, Sato R, Takahashi K, Arihara Z.
    Tohoku J Exp Med; 2018 Jan 02; 244(1):33-40. PubMed ID: 29343652
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. A Rare Case of Severe Diabetic Ketoacidosis in a Patient With Metastatic Renal Cell Carcinoma Being Treated With Nivolumab.
    Bazzi T, Gupta E, Mohamed A, Vashi M.
    Cureus; 2022 Sep 02; 14(9):e29537. PubMed ID: 36312693
    [Abstract] [Full Text] [Related]

  • 20. Simultaneous onset of type 1 diabetes mellitus and silent thyroiditis under durvalumab treatment.
    Mengíbar JL, Capel I, Bonfill T, Mazarico I, Espuña LC, Caixàs A, Rigla M.
    Endocrinol Diabetes Metab Case Rep; 2019 Jul 15; 2019(1):. PubMed ID: 31310083
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.